Dicyclomine Hydrochloride

# Dicyclomine hydrochloride ## Overview - **Classification**: Anticholinergic, Antispasmodic - **Mechanism**: Directly smooth muscle relaxant and selectively blocks muscarinic receptors (M-cholinergic receptors). Reduces activity of the parasympathetic system, decreasing GI motility and secretion. ## Primary Indications 1. **Irritable Bowel Syndrome (IBS)**: Treatment of functional bowel disorders presenting as cramping, hypermotility, and pain. 2. **Functional GI Disorders**: Relief of symptoms associated with excessive intestinal spasms. ## Adult Dosing ### Standard Dosing **Irritable Bowel Syndrome (IBS)** - **Dose**: Initially **20 mg** - **Frequency**: **QID** (Four times daily) - **Route**: Oral (Capsule or Tablet) - **Max Dose**: Up to **40 mg QID** (total **160 mg/day**) if initial dose is tolerated but inadequate. **Acute Symptoms (Injection)** - **Dose**: **10 mg** - **Frequency**: **QID** - **Route**: Intramuscular (IM) ONLY - **Duration**: Should be discontinued and switched to oral route as soon as possible (usually 1-2 days). ### Dose Adjustments - **Renal Impairment**: Caution advised; start at lower range (**10 mg QID**) and titrate carefully. Significant renal impairment may warrant avoidance. - **Hepatic Impairment**: Use with caution due to lack of specific data; monitor closely for increased side effects. - **Elderly Patients**: Start low (**10 mg QID**); increased risk of CNS and anticholinergic effects (confusion, glaucoma exacerbation). ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: **Contraindicated** - **Safety Concern**: Severe respiratory symptoms (apnea, dyspnea, seizures, cardiovascular collapse) have been reported. ### Infants (1-6 months) - **Dose**: **Contraindicated** - **Safety Concern**: Associated with high risk of severe anticholinergic toxicity and death. ### Children (6 months to 2 years) - **Dose**: **Contraindicated** (Safety/efficacy not established) - **Maximum**: **0 mg** ### Children (2 - 12 years) - **Dose**: **10 mg** - **Frequency**: TID (Three times daily) or QID - **Maximum**: **40 mg/day** total ### Adolescents (13-18 years) - **Dose**: Start with adult dose (**20 mg QID**) - **Maximum**: **160 mg/day** ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to dicyclomine or anticholinergics. - **Absolute**: **Infants < 6 months old** (risk of death). - **Absolute**: Obstructive uropathy, GI tract obstruction (e.g., paralytic ileus). - **Absolute**: Severe ulcerative colitis, reflux esophagitis. - **Absolute**: Myasthenia gravis, uncontrolled narrow-angle glaucoma. ### Common Adverse Effects - **Very Common (>10%)**: Dry Mouth, Dizziness, Blurred Vision. - **Common (1-10%)**: Nausea, Constipation, Drowsiness, Nervousness. - **Serious but Rare**: Hyperpyrexia/heat stroke, Acute psychosis, Cardiac arrhythmia (tachycardia). ### Key Drug Interactions - **Anticholinergic Agents (e.g., TCAs, antihistamines)**: Enhanced anticholinergic toxicity (dry mouth, urinary retention, confusion). Requires close monitoring. - **Opioids**: Increased risk of severe constipation and potential paralytic ileus. Monitor bowel function. - **Antacids**: Decrease oral absorption of dicyclomine. Separate administration by at least **2 hours**. ## Monitoring & Follow-up - **Before Treatment**: Baseline assessment for obstructive GI/urinary conditions, history of glaucoma. - **During Treatment**: Monitor for urinary retention, severe constipation, and changes in mental status (especially in the elderly). - **Clinical Signs**: Assess improvement in GI symptoms; watch for signs of overheating (hyperpyrexia), particularly in high temperatures. ## Clinical Pearls - 💡 **Tip 1**: Due to risk of neurotoxicity, Dicyclomine should **never be given IV**; only IM or orally. - 💡 **Tip 2**: Advise patients to avoid operating heavy machinery until response to drug is known due to dizziness and blurred vision. - 💡 **Tip 3**: Counsel patients on managing dry mouth (sugar-free candy/gum) and how to recognize signs of overheating (reduced sweating). > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.